← back to search

Frank Speleman

University of Padua · IT
Area of research
Neurology · Cancer Research
Research interest
Research interests include Biology, Cancer research, Neuroblastoma, microRNA, Gene, and Medicine.
h-index
citations
2,794
works
31
NIH funding
primary concept
email

Recent publications

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
JCO Precision Oncology 2026cited by 1position: middledoi
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
Science Advances 2022cited by 47position: lastdoi
Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma
Life Science Alliance 2021cited by 4position: middledoi
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
Scientific Reports 2020cited by 28position: lastdoi
PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis
Leukemia 2020cited by 26position: middledoi
A mechanistic classification of clinical phenotypes in neuroblastoma
Science 2018cited by 334position: middledoi
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
Nature Communications 2018cited by 110position: lastdoi
LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Clinical Cancer Research 2018cited by 89position: middledoi
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
JCI Insight 2018cited by 31position: middledoi
Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice
Scientific Reports 2018cited by 27position: middledoi
ALK positively regulates MYCN activity through repression of HBP1 expression
Oncogene 2018cited by 25position: lastdoi
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
bioRxiv (Cold Spring Harbor Laboratory) 2018cited by 2position: middledoi
MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma
Oncotarget 2016cited by 37position: middledoi
LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19
Haematologica 2016cited by 23position: middledoi
Mutational dynamics between primary and relapse neuroblastomas
Nature Genetics 2015cited by 318position: middledoi
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Clinical Cancer Research 2015cited by 180position: middledoi
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Clinical Cancer Research 2015cited by 85position: middledoi
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia
Blood 2015cited by 63position: middledoi
MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma
Cancer Letters 2015cited by 50position: lastdoi
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Nature 2014cited by 633position: middledoi
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
Oncogene 2014cited by 147position: middledoi
miR‐542‐3p exerts tumor suppressive functions in neuroblastoma by downregulating <scp>S</scp> urvivin
International Journal of Cancer 2014cited by 84position: middledoi
Refinement of the critical 2p25.3 deletion region: the role of MYT1L in intellectual disability and obesity
Genetics in Medicine 2014cited by 59position: middledoi
MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
Oncotarget 2014cited by 45position: lastdoi
The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia
Haematologica 2014cited by 45position: lastdoi
CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
PLoS ONE 2014cited by 22position: middledoi
Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma
Cancer Research 2014cited by 1position: middledoi
Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia
PLoS Genetics 2013cited by 137position: middledoi
Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
Cancer Research 2013cited by 57position: middledoi
Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
PLoS ONE 2013cited by 44position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Johannes H. Schulte · Universitätsklinikum Tübingen10 papers (2013–2020)Katleen De Preter · VIB-UGent Center for Medical Biotechnology9 papers (2013–2020)Jo Vandesompele · Shanghai Cell Therapy Research Institute7 papers (2013–2018)Kristina Althoff · German Cancer Research Center6 papers (2014–2015)Angelika Eggert · DKFZ-ZMBH Alliance6 papers (2013–2015) · 6 papers (2014–2015)Frank Westermann · Heidelberg University6 papers (2013–2021)Alexander Schramm · Klinik und Poliklinik für Kinder- und Jugendmedizin5 papers (2013–2015)Pieter Van Vlierberghe · University of Technology Sydney5 papers (2014–2020)Pieter Mestdagh · Ghent University4 papers (2013–2014) · 4 papers (2014–2016)Gian Paolo Tonini · University of Padua3 papers (2013–2014)Candy Kumps · University of Lausanne3 papers (2013–2020)Geneviève Laureys · Ghent University Hospital3 papers (2013–2020)Emma Bell · Ontario Institute for Cancer Research3 papers (2014–2015) · 3 papers (2013–2020) · 3 papers (2015–2016)Andrea Odersky · Essen University Hospital3 papers (2014–2015)Glenn M. Marshall · The University of Sydney3 papers (2014–2018)Daniel R. Carter · Children's Cancer Institute Australia3 papers (2014–2018)